Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion

NCT00913744 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Exudative Age-Related Macular Degeneration
Focal Vitreomacular Adhesion

Interventions

DRUG: Ocriplasmin
DRUG: Sham injection

Sponsor

ThromboGenics